6/27/2013

A division of the Netherlands' Ministry of Economic Affairs granted Kiadis Pharma a loan worth around $3.9 million to support midstage trials of ATIR. The drug candidate is designed to permit stem cell transplantations for blood cancer patients with partially mismatched or haploidentical donors.

Related Summaries